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Abstract
DNA damage response (DDR) genes and pathways controlling the stability of HPV episomal DNA are reported here. We set
out to understand the mechanism by which a DNA-binding, N-methylpyrrole-imidazole hairpin polyamide (PA25) acts to
cause the dramatic loss of HPV DNA from cells. Southern blots revealed that PA25 alters HPV episomes within 5 hours of
treatment. Gene expression arrays identified numerous DDR genes that were specifically altered in HPV16 episomecontaining cells (W12E) by PA25, but not in HPV-negative (C33A) cells or in cells with integrated HPV16 (SiHa). A siRNA
screen of 240 DDR genes was then conducted to identify enhancers and repressors of PA25 activity. Serendipitously, the
screen also identified many novel genes, such as TDP1 and TDP2, regulating normal HPV episome stability. MRN and 9-1-1
complexes emerged as important for PA25-mediated episome destruction and were selected for follow-up studies. Mre11,
along with other homologous recombination and dsDNA break repair genes, was among the highly significant PA25
repressors. The Mre11 inhibitor Mirin was found to sensitize HPV episomes to PA25 resulting in a ,5-fold reduction of the
PA25 IC50. A novel assay that couples end-labeling of DNA to Q-PCR showed that PA25 causes strand breaks within HPV
DNA, and that Mirin greatly enhances this activity. The 9-1-1 complex member Rad9, a representative PA25 enhancer, was
transiently phosphorylated in response to PA25 treatment suggesting that it has a role in detecting and signaling episome
damage by PA25 to the cell. These results establish that DNA-targeted compounds enter cells and specifically target the
HPV episome. This action leads to the activation of numerous DDR pathways and the massive elimination of episomal DNA
from cells. Our findings demonstrate that viral episomes can be targeted for elimination from cells by minor groove binding
agents, and implicate DDR pathways as important mediators of this process.
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viral DNA instability and rapid loss from cells by an unknown
mechanism.
HPV must evade innate cellular defense mechanisms to be
maintained in cells [7,10,11]. DNA damage response (DDR)
pathways are increasingly recognized as a central host defense
mechanism that must be subverted, and are often utilized, by
DNA viruses to establish a persistent infection [9,12,13]. DNA
viruses have a complex relationship with DDR pathways [12].
Foreign DNA activates the DDR, which protects the host cell
genome. Conversely, viruses counteract and often exploit the
DDR to promote their survival and life cycle. The ataxiatelangiectasia mutated (ATM) and ATM and Rad3-related (ATR)
serine/threonine protein kinases are important sensors of DNA
damage. ATM responds to dsDNA breaks (DSBs), while ATR
senses a variety of DNA insults such as stalled replication forks and
ssDNA exposure and harm [14]. ATM and/or ATR signaling is
activated by most DNA viruses due to recognition of viral genomes
as damaged DNA, in response to replication stress, or by viral
activation of these pathways to promote facets of its life cycle [15].
Cells carrying HPV episomes show constitutive activation of DDR

Introduction
Human papillomavirus (HPV) infection results in establishment
of the viral genome as a circular, multi-copy, extrachromosomal
double-stranded DNA (dsDNA), or episome, within the proliferating cell compartment of stratified squamous epithelia [1].
Persistent HPV infection, defined as the length of time that
HPV DNA is detectable following an initial positive clinical test, is
considered the greatest risk factor for HPV-dependent carcinogenic progression [2,3,4]. Controversy exists over what constitutes
or abets a persistent infection (see [3] for discussion), but factors
such as status of host immune system and viral immune evasion
appear to be key [3,5,6,7]. Antiviral therapies for HPV remain an
important, unmet medical need, but have not been developed for a
variety of reasons including the small HPV genome, which
encodes few traditional antiviral targets. Therefore, alternative
approaches to antiviral therapies are important. To this end, a
series of DNA-binding, N-methylpyrrole-imidazole hairpin polyamides (PAs) that target HPV episome DNA for elimination from
cells has been described [8,9]. These compounds trigger massive

PLOS ONE | www.plosone.org

1

October 2013 | Volume 8 | Issue 10 | e75406

DNA Damage Repair Genes and HPV Episome Stability

DNA-targeted compound, and suggest that these pathways
regulate the initiation of a poorly understood process leading to
viral DNA destruction.

elements including ATR, ATM, Chk1, Chk2, BRCA1, and Nbs1
[9,16,17], and inhibition of the ATR/Chk1 pathway results in loss
of HPV episomes from cells [9]. HPV-encoded proteins have also
been shown to directly activate DDR pathways. HPV E1, the viral
helicase that licenses HPV replication, activates ATM and ATR
while causing dsDNA breaks (DSBs), which are impaired by E2
[18,19]. HPV E7 binds ATM and promotes Chk2 regulated
caspase-dependent activation of HPV E1, and pharmacological
inhibition of ATM impedes productive HPV replication in
differentiating keratinocytes [16].
Other DDR response pathways have also been implicated in
HPV infection. Fanconi Anemia (FA) is a genome instability
syndrome causing extremely high rates of squamous cell carcinoma (SCC). FA is caused by mutation of 1 of the 15 members of the
FA pathway, which assemble in the nucleus to form a large
ubiquitin ligase important in DNA repair [20]. While there are
conflicting reports on the role of HPV in SCC in FA patients
[21,22], the intact FA pathway appears to function as an HPV
suppressor in laboratory studies [23,24]. Homologous recombination (HR) and non-homologous end-joining (NHEJ) are the two
primary processes of dsDNA break repair in mammalian cells.
The Mre11-Rad50-Nbs1 (MRN) complex plays a role in both HR
and NHEJ as a dsDNA break sensor [25,26]. CtIP, a physical and
functional partner of the MRN complex, is also required for
efficient HR and is essential for dsDNA break resection [27]. The
DNA viruses SV40 and EBV have been shown to use HR for
efficient replication [15], and multiple members of the HR
pathway are recruited to HPV nuclear foci where they play a role
in productive replication and, possibly, in HPV episome maintenance [16,28]. Our own studies demonstrated that ATM
knockdown by siRNA, but not pharmacological inhibition, results
in significant HPV episome loss from cells suggesting a structural,
rather than enzymatic, role in HPV episome maintenance [9].
Understanding the mechanism by which antiviral PAs destabilize and eliminate HPV episomes from cells may shed light upon
viral DNA evasion of innate immunity and persistence in cells
[8,9]. The degree and time course of HPV episome loss suggests
that PAs trigger active elimination of viral DNA by the cell.
Smaller polyamides and other minor groove-binding agents are
known to affect DNA structure in a number of quantitative and
qualitative ways [29,30,31,32]. For example, 6- and 8-ring
polyamides, significantly smaller than PA25, were shown by gel
shift assays of ligation ladders to affect DNA bending in a manner
dependent on DNA and polyamide sequence. The consequences
of binding of larger PAs (such as PA1, PA25, and other anti-HPV
compounds which bind to a minimum of ,1 helical turn) for DNA
structure and conformation are unknown.
Here we show that PA25 causes HPV-specific alterations in
expression of numerous DDR genes. A siRNA screen targeting
240 DDR genes was then utilized to identify repressors and
enhancers of PA25 antiviral activity with a high degree of
statistical confidence. The 9-1-1 and MRN complexes stood out as
significant contributors to PA25 activity based upon results from
the siRNA screen and gene expression studies, and were selected
for follow up studies. PA25 was found to trigger phosphorylation
of 9-1-1 complex member Rad9 in a time- and HPV-dependent
manner. PA25 is also shown to cause dsDNA breaks within the
HPV genome, and this activity is enhanced by Mirin, an inhibitor
of Mre11 endonuclease activity, which sensitizes HPV episomes to
PA25. Together our findings show that PA25 causes structural
alterations and DSBs within HPV episomes resulting in activation
of DDR pathways which are rate limiting for episome loss. These
findings contribute to understanding how DDR pathways control
the massive instability of HPV episomes in the presence of a novel
PLOS ONE | www.plosone.org

Materials and Methods
Cells and Cell Culture
HPV-maintaining human keratinocytes were maintained and
passaged as previously described [8,33]. C33A and SiHa cells
(ATCC, Rockville, MD) were cultured in Dulbecco’s Modified
Eagle’s Media containing 10% fetal bovine serum (Invitrogen).
Fluorescence activated cell sorting (FACS) was conducted as
previously described [9].

Quantification of HPV Episome Levels
HPV episome copy number was tracked via Q-PCR using L1specific primers and TaqManH probe as previously described
[8,9,33]. IC50 values were calculated by non-linear regression
using XLFIT (IDBS). For drug treatment, W12E cells were pretreated with 100 mM Mirin [34] (Sigma, Cat # M9948) or 0.1%
DMSO for 24h. Media was removed and fresh media containing
the indicated doses of PA25 or 0.1% DMSO was added, and cells
incubated an additional 24h. Total DNA was harvested using
DNAzol (Invitrogen, Cat # 10503-027) according to manufacturer’s recommendation, and 20 ng total DNA analyzed as above
by Q-PCR.

Polyamide Preparation
Polyamides 11 (PA11) and 25 (PA25) were prepared by solid
phase, Boc-protected peptide methodology as reported [35].
Purification was carried out as described in the same literature
report, using reverse-phase HPLC with 0.1% trifluoroacetic acid
in the mobile phase. Analytical HPLC/mass spectrometry showed
high purity. The exact mass of compound 25 was reported
previously to help characterize its composition [8]. PA11 was also
reported previously by another group [36], but no characterization
data were given. Therefore, we provide the PA11 High Resolution
Mass Spectral data here: C58H71N21O10 M+ (theoretical)
1221.5684 M+ (measured, ESI HRMS) 1221.5707. Detailed
chemical characterization of both compounds, for example by
600 MHz 1H and 13C NMR, will be reported in a more chemical
journal as part of the characterization of our entire library of active
and inactive polyamides.

Southern Blotting
T75 flasks of W12E cells were treated with 1 mM PA25 or 0.1%
DMSO for the indicated times. Total cellular DNA was extracted
by lysing the cells with 20 mM Tris-HCL (pH 8), 100 mM EDTA,
150 mM sodium chloride, and 1% sodium dodecyl sulfate (SDS)
containing 50 ug/ml Proteinase K (Invitrogen, Cat # 100005393)
and incubated overnight at 37uC. Samples were extracted with
phenol:chloroform:isoamyl alcohol (25:24:1, v/v) until interphase
was clear followed by 2X chloroform extraction. Total DNA was
precipitated with 2 volumes of ethanol and incubated overnight at
220uC. Pellets were re-suspended in 0.5 mL Tris-EDTA (TE)
buffer (PH 8.0), sheared by passing through an 18-gauge needle
and 50 ug/ml RNAse A (Sigma R4642) added for 1h at 37uC.
DNA was again phenol:chloroform extracted and ethanol
precipitated. DNA pellets were re-suspended in TE buffer and
5 ug was digested with BamHI or HindIII overnight. DNA was
electrophoresed in the presence of 0.5 ug/mL ethidium bromide
at 5 V/cm for 18h, transferred onto positively-charged nylon
membranes and probed with full-length HPV16 genomic DNA
(random-primed with [32P]dCTP). Membranes were exposed to
2
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looked at the effects of siRNAs on HPV episome levels after
treatment with PA25. Set 1 positive hits were defined as siRNAs
that gave a $2-fold change in HPV episome copy number in $5
out of 6 pair-wise comparisons in at least 3 out of 4 independent
experiments when compared with the 6 control values on each
day. Set 2 positive hits, which represent gene effects on PA25
antiviral activity, were identified as those siRNAs that resulted in a
$2-fold difference in episome copy number as determined from
the DDCt (Set 2 value - Set 1 value) for any given siRNA. Gene
hits for Set 2 also needed to be significant in at least 3 out of 4
independent experiments. The statistical methods employed are
presented in greater detail in Supporting Information (Statistical
Methods S1 in File S1, Figures S3 and S4 in File S1, and Table S2
in File S1). A list of all 240 genes employed in the siRNA screen is
provided in Table S3 in File S1.

phosphor screens and imaged with a Molecular Dynamics
Phosphorimager.

Gene Expression Arrays and RT-PCR
W12E cells were seeded onto 6-well plates (approx. 100,000
cells) and the following day treated with 10 uM PA25, 10 uM
control PA11, or 0.1% DMSO in W12E cell growth media. RNA
was extracted 48hr later using the RT2 qPCR-Grade RNA
Isolation Kit (SABiosciences, Cat # PA-001) and quality
confirmed by agarose gel assessment of 18S/28S ribosomal
RNA. RNA from each treatment group was reverse transcribed
using Maxima First Strand cDNA Synthesis Kit (Fermentas, Cat
# K1641). Drug effects on gene expression were analyzed for the
following pathways: Human Apoptosis (Cat # HPA-I), Human
DNA Repair I & II (Cat # HDRL-I and HDRL-II), and Human
Cell Cycle (Cat # HCC-I). All PCR Arrays were obtained from
RealTimePrimers. Primers were supplied lyophilized in 96-well
plates with each pathway array containing unique gene-specific
primer pairs for 88 target genes (TG). An additional eight primer
pairs were supplied for 8 control genes. Primer stocks were resuspended at 10 mM and added to PCR reactions at [100 nM]
final along with Sybr Green Master Mix (Fermentas, Cat #
K0221) and 2.5 ng cDNA per well of 96-well plates. Q-PCR was
performed using the following cycling conditions: 1X 95uC for 10
min followed by 40 cycles of 95uC for 10 sec, 58uC for 45 sec.
Three independent experiments were performed for each array,
and the DCt calculated for each target gene (TG) against the
average of all control genes (CG) as follows (DCt = Ct (CG) – Ct
(TG). This approach yielded 9 pair-wise comparisons for each
gene (3 DMSO-treated DCt values X 3 PA-treated gene DCt
values). Genes were scored as affected by PA if there was a twofold or greater change (2-fold change = 1 DDCt value) in gene
expression compared to DMSO-treated cells in $ 7/9 pair-wise
comparisons.

Validation of Gene Hits
Genes were confirmed if at least 2 out of the 4 individual siRNA
sequences recapitulated the data from the initial screen. Gene hits
were verified by de-replication of Dharmacon SmartPool siRNAs
into the 4 individual sequences. Singular siRNAs were reverse
transfected into W12E cells at a final concentration of 50 nM, and
then cultured for 72h at which time media was changed and either
1 mM PA25 or 0.1% DMSO was added. Cells were cultured an
additional 24h, DNA harvested, and Q-PCR performed as
described for the initial screen.

Gene-specific siRNA knockdown and off-target effects
A subset of siRNAs represented in the siRNA screen was
randomly chosen to analyze for specific siRNA knockdown and
determination of potential off-target effects by reverse transcription PCR (RT-PCR). W12E cells were split onto 6-well plates and
transfected 48h later with 50 nM siRNA (Dharmacon) using 3 mL
transfection reagent per well in a total volume of 2 mL/well. Cells
were cultured for 72h with siRNAs at which time RNA was
extracted and reverse transcribed using Maxima First Strand
cDNA Synthesis Kit (Fermentas, Cat #K164125). 2.5 ng of
cDNA was used per Q-PCR reaction (SYBRH Green; Roche)
using PCR primer sets obtained from IDT (see Table S4 in File
S1) at a final concentration of 300 nM. All 22 primer sets were run
against each siRNA transfection in a matrix to validate siRNA
specificity and potential off-target effects. PCR conditions were as
follows: 10 min 95uC, 40 cycles at 95uC 10 sec, 60uC 10 sec, 72uC
10 sec.

siRNA Screen
Targeted siRNAs were purchased from Dharmacon (Dharmacon ON-TARGETplusRTFH SMARTpoolH siRNA Library Human DNA Damage Response; H-106005, Lot 11152) and
supplied lyophilized on 96-well tissue-culture plates. A total of 240
genes were provided on three separate 96-well plates, with each
plate containing 80 unique genes as well as non-targeting (NT) and
cyclophilin-targeting control siRNAs. Each of the 4 independent
experiments was conducted against all 240 genes along with
controls. Transfection reagent (DharmaFECT1; Dharmacon cat#
T-2001-02) was diluted to a final 0.15 mL per well with
Dharmacon Cell Culture Reagent (cat# B-004500-100). 25 mL
was added to each well and incubated 30 min at room
temperature to fully re-suspend siRNAs. W12E or HPV31
maintaining cells were plated at 4500 cells/well in 100 mL
complete E media (no antibiotic) with J2 3T3 feeder layer. Cells
were incubated 72hr with siRNAs, media was changed to include
0.1% DMSO or 1 mM PA25 in 100 mL complete E media (no
antibiotic), and then cells incubated an additional 24hr. At the end
of the treatment period, cells were lysed and DNA harvested using
a Wizard SV 96 Genomic DNA Purification Kit (Promega
#A2370). siRNA and PA25 effects on cellular HPV episome levels
was measured via TaqManH PCR using HPV16 or HPV31specific L1 primers as previously described [8,9,33].
Statistical analysis of the siRNA screen is described in detail in
Supporting Information (Statistical Methods S1 in File S1, Figures
S3 and S4 in File S1, and Table S2 in File S1). Briefly, two sets of
data were generated for each of the 4 experiments. Set 1 examined
the effects of 240 siRNAs on HPV episome levels, while set 2
PLOS ONE | www.plosone.org

Western Blotting
T75 flasks of W12E and C33A cells were treated with 1 mM
PA25 and harvested at different times. Cells were trypsinized,
washed with ice-cold phosphate-buffered saline (PBS), and lysed in
radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCL
pH 7.5, 150 mM NaCl, 1% NP-40, 2% sodium deoxycholate,
0.1% SDS) supplemented with 2X Halt Protease & Phosphatase
Inhibitor Cocktail (Thermoscientific, catalog no. 1861284).
Lysates were incubated with 150 U/mL DNAse I (Thermoscientific, catalog no. 89835) for 30 minutes at room temperature with
mixing. Protein concentration was determined by BCA Assay
(Thermoscientific, catalog no. 23227) and 50 mg protein separated
on Tris-Glycine 4220% gels (NuPAGE). Gels were transferred
onto PVDF membranes with an iBLOT system (Invitrogen), and
membranes blocked in 5% milk/TBST (20 mM Tris-HCL
pH 7.5, 150 mM NaCl, 0.1% Tween 20) overnight at 4uC. Blots
were incubated at room temperature for 2hr with phospho-Rad9
antibody (1:200; Santa Cruz, sc-130213) or pan-Rad9 antibody
(1:200; Santa Cruz, sc-32489) and detected with goat anti-rabbit
3
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Figure 1. Antiviral activity and structure of anti-HPV N-methylpyrrole-imidazole polyamides following 48 hours of treatment in
W12E cells. A. PA1 and PA25 dramatically decrease HPV16 episome levels in W12E cells while the related PA11 has no effect. B. Structure of PA11. C.
Structure of PA25.
doi:10.1371/journal.pone.0075406.g001

poly-HRP secondary antibody (1:25,000; Pierce, Cat # 32260)
and donkey anti-goat IgG-HRP secondary antibody (1:25,000;
Santa Cruz, sc-2020), respectively.

reaction components except TdT. DNA was isolated from
unincorporated nucleotides by ethanol precipitation. BiotinStreptavidin pull-down assays were subsequently conducted as
follows: 50 uL of Streptavidin-Sepharose 4B Conjugate beads
(Invitrogen, Cat # 43-4341) were used for each pull-down; to
block non-specific binding, Sepharose beads were pre-incubated in
500 uL binding/wash buffer (BWB, 20 mM Tris-HCL pH 8.0,
5 mM EDTA, 2 M NaCl, 0.1% NP40) containing 100 ug salmon
sperm DNA and 100 ug purified BSA for 1h at RT with shaking;
biotin end-labeled DNA was resuspended in 100 uL BWB
containing 100 ug of both salmon sperm DNA and BSA, added
to pre-blocked Sepharose beads and incubated 30 min at RT.
Beads were washed 5X with BWB and DNA eluted by
resuspending beads in 25 uL 95% formamide, 10 mM EDTA
pH 8.0 and incubating at 65uC for 10’. Eluted DNA was then
diluted 10-fold with water. HPV DNA copy number was
quantified via TaqMan real-time PCR (described above). Specific
pull-down of tailed HPV16 was calculated by subtracting total
copies pulled down in the absence of TdT (non-specific) from total
copies pulled down in the TdT-biotin tailing reaction (specific).

Detection of HPV DNA Breaks by End-labeling Coupled
to Q-PCR (ELCQ)
W12E cells were pre-treated with 0.1% DMSO or 100 uM
Mirin for 24h followed by treatment with 0.1% DMSO or 1 uM
PA25 for 5h. HPV16 episomal DNA was isolated from W12E cells
by standard alkaline lysis plasmid preparation procedures [37].
Following neutralization, the supernatant was cleared by centrifugation and DNA precipitated by addition of 0.7X volume
isopropanol. DNA pellets were washed 3X with 70% ethanol and
resuspended in TE buffer (pH 8.0). Terminal deoxynucleotidyl
transferase (TdT) tailing reactions were conducted in the presence
of Biotin-16-dUTP as follows: 20 uL reactions containing 1 ug
DNA, 2 uL nucleotide mix (35 uM Biotin-16-dUTP final, Roche,
Cat # 11093070910), 4 uL [25 mM] CoCl2 (5 mM final), 4 uL
5X TdT buffer, and 1 uL TdT enzyme (400U, Roche, Cat #
03333566001) were incubated for 30 min at 37uC. For each DNA
sample, a negative control reaction was set up containing all
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Since a number of cell cycle genes exhibited altered expression
in the presence of PA25 (Table 1), the effects of 10 mM PA25 on
cell cycle progression was next examined. FACs analysis suggested
that W12E cell progression through G2/M and S phase were
slowed by PA25 resulting in small increases of cells in these phases
with a concomitant decrease of the G0/G1 population (Figure S2
in File S1). However, these effects do not significantly alter cell
growth since PA25, or other PAs, have not been found to effect
cell numbers in cell viability assays [8].

Results
Compounds that Destabilize HPV Episomes
PA1 and PA25 potently reduced HPV episome copy number in
W12E cells while a related compound, PA11, had no effect (Figure
1A). The structure of PA25 and PA11 are shown (Figure 1B and
1C); the structure of PA1 was previously published [8]. Southern
blots were conducted to examine the effects of PA25 on HPV
DNA over 48 h. of treatment (Figure 2). The blots showed good
agreement with compound Q-PCR potency data results (Figure
1A) with a time-dependent decrease in the BamH1 linearized
episomal DNA observed. The corresponding blots of uncut HPV
DNA (HindIII) did not show the clear quantitative decrease in
viral DNA that was exhibited by the blots of linearized samples
and Q-PCR, but PA25-dependant, qualitative changes to the OC
and SC episome forms were noted in the later stages of the time
course (Figure 2). PA25 (1 mM) caused both forms to migrate
aberrantly and diffusely, a change that was particularly apparent
after 8 h. of treatment. The lack of quantitative signal was
attributed to increased hybridization of probe with the smeared
viral DNA at later time points. Once the HPV episomal DNA was
linearized with BamH1, all bands collapsed into a single band on a
blot that was highly quantitative and correlated well with Q-PCR
data (Figure 2). No evidence of viral DNA integration is seen in
either blot, consistent with previous findings [8,9].

A siRNA Screen for DDR Genes that Modify HPV Episome
Stability
These results indicated that DDR pathways are triggered by
PA25 and might play a role in its antiviral activity. With this as
rationalization, a siRNA screen was undertaken to examine the
role of 240 DDR genes in episome stability, and in HPV episome
instability triggered by PA25. The overall screen design included 4
complete experiments: the first three experiments focused on
HPV16 episome fate in W12E cells, while the final experiment
examined HPV31 episomes in HPV31-containing cells (Figure 4).
These experimental replicates were necessary to allow the
identification of significant changes in episome copy number with
a high degree of statistical confidence, and to assess episome
stability for two HPV genotypes in different cellular backgrounds.
Each experiment provided DCt values for HPV episomes in the
presence of control siRNAs and 240 DDR siRNAs for cells
receiving either vehicle (0.1% DMSO; Set 1) or 1 mM PA25 (Set
2). Thus, the data provided the opportunity to assess the effects of
DDR siRNAs on HPV episome levels under conditions of stable
maintenance (0.1% DMSO vehicle) or under conditions of
massive instability (1 mM PA25) (Figure 4).
An evaluation of variability among siRNA control and
experimental values assessed the degree of reproducibility of the
screen between experiments, which were conducted on separate
days. Popular measures such as the Z-factor that provides an
appraisal of data quality [38] were not possible since no positive
controls were available for use in the study. Therefore calculation
of the coefficient of variation (CV) was performed for each
experimental day for the control data. The CVs were all found to
be well below 5% and fairly consistent across all experimental days
indicating a high degree of experimental reproducibility (see:
Statistical Methods S1 in File S1). Further analysis of the data then
ensued.
Initially, hierarchical clustering was employed to examine the
similarity of siRNA effects on Ct values generated by Set 1
(receiving 0.1% DMSO) over the 4 different experiments
(Figure 5). This information was important because it helped
determine whether Experiment 4 (conducted with HPV31+ cells)
should be incorporated in the analysis with the other three
experiments conducted with HPV16+ cells. Hierarchical clustering revealed that the two experiments with greatest similarity were
2 and 3 (Figure 5). Experiment 4 was most similar to 2 and 3, and
Experiment 1 was the least related (Figure 5). In other words, the
results demonstrated that the stability profile of HPV31 episomes
in a screen of 240 siRNAs fell within the range of stability profiles
generated for HPV16 episomes (Figure 5). Therefore, further
analyses reported here were conducted with all 4 data sets.
The success of a screening experiment is dependent upon the
correct siRNA pool (or compound) being arrayed in the proper
well. As a test of the veracity of the manufacturer’s labeling and
the specificity of the siRNA pools for the targeted gene, 22 DDR
siRNAs were tested in a matrix for their effects on expression of all
22 target genes by Q-RT-PCR (Figure 6). All 22 siRNAs
specifically down-regulated the proper target gene in comparison

PCR Array Studies of PA25 Effects on Gene Expression
These results showed that the HPV episome was destabilized
and lost following PA25 treatment, and suggested that it might be
physically altered by PA25. A series of PCR array experiments
were next conducted with HPV16-maintaining W12E cells in
order to explore the effects of PA25 on gene expression. PA11 was
run in these experiments as a control compound. PCR arrays
covering apoptotic, cell cycle, and DDR pathways were selected
for these initial experiments. PA11 did not significantly affect the
expression of any genes according to our criteria: no genes gave a
DDCt of $1 in $7 of 9 pair-wise comparisons (Figure 3A). On the
other hand, PA25 significantly altered the expression of numerous
genes most of which exhibited decreased expression and were
members of DDR or cell cycle pathways (Figure 3B and Table 1).
RAD1 and NBS1 gave the greatest DDCt values signifying downregulation of these genes by 67- and 35-fold respectively (Figure
3B and Table 1). CtIP (RBBP8) was also among the most affected
genes (21-fold down regulation). It was of high interest that
MRE11 was also significantly down-regulated since it partners
with NBS1 in the MRN complex, and in conjunction with CtIP
promotes end resection during DSB repair (Figure 3B and Table
1). Three members of the Fanconi Anemia pathway (FANCB,
FANCC, and FANCL) were also down regulated (Table 1). Only 3
genes showed statistically significant, increased expression, albeit
marginal, in response to PA25: p21 (CDKN1A), POLM, and
TREX1. A summary of all genes exhibiting significantly altered
expression in the presence of PA25 is provided in Table 1.
To determine if changes in gene expression were due to PA25
interaction with HPV episomes, the same screen was conducted in
the HPV-negative C33A cervical cancer cell line and in the
HPV16 positive SiHa cell line. In both cases, the expression of
only 7 genes was altered by PA25 treatment (Figure S1 and Table
S1 in File S1), and only one of these genes (LIG3 in C33A cells)
was among those altered in the HPV16-positive W12E cells. The
genes altered in both C33A and SiHa cells showed remarkable
similarity with only one gene difference for each cell type (Figure
S1 and Table S1 in File S1).

PLOS ONE | www.plosone.org
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Figure 2. Southern blots of linearized (left) and intact (right) HPV16 episomes over time following treatment with 1 mM PA25 for
48 hours. The blots are loaded identically except HPV16 was linearized by BamH1 in one set of samples (left) or digested with HindIII, which does
not restrict viral DNA (right). An additional, over-exposed HindIII blot is also provided. OC: open circle; SC: super-coiled.
doi:10.1371/journal.pone.0075406.g002

Another 4 genes were members of excision repair pathways
including nucleotide excision repair (NER; RAD23A), base
excision repair (BER; NEIL3, RAD1), and mismatch repair
(MMR; MLH3). The remaining 6 genes included TP53,
UBE2V2, MTOR, and genes implicated in DNA adduct repair
(TDP1, TDP2), and post-replication repair (RAD18).

to the 21 other genes in the matrix. While some slight off-target
effects were noted, the resulting diagonal, mid-linear effect in the
heat map indicated that the siRNAs possessed the expected
specificities (Figure 6).

Identification of DDR Genes that Control Stable HPV
Episome Levels

Identification of Enhancers and Repressors of PA25
Activity

Those siRNAs that significantly altered cell HPV episome
content in the absence of PA25 were identified from the Set 1 data
(Table 2); 18 genes were identified from the screen as being
potentially important for HPV episome maintenance. Of these 18
genes, 7 were found to limit episome levels (knockdown resulted in
increased episome numbers), while 11 genes were found to
augment episome levels (knockdown caused episome loss)
(Table 2). Importantly, 6 of the 18 implicated genes belonged to
either homologous recombination (HR) or Fanconi Anemia (FA)
pathways, which have both been previously implicated in episome
maintenance. A total of 5 significant genes are involved in DSB
repair including 3 associated with HR (ATM, RTEL1, RUVBL2)
and 2 with non-homologous end joining (NHEJ; LIG4, POLM).
PLOS ONE | www.plosone.org

By subtracting the Ct value for a given Set 1 siRNA from the
corresponding Set 2 value (DDCt, or difference of the difference),
the siRNAs that significantly increased or decreased the activity of
PA25 were identified (Figure 7, Table 3). A total of 21 genes were
initially identified as significant in the screen. Each significant gene
was then subjected to a validation test that required at least 2 of
the 4 siRNAs from the original siRNA pool cause $2-fold change
in HPV episomes in the presence of PA25. These studies
confirmed 20 genes: 16 genes were designated as PA25 repressors
because their knockdown resulted in increased PA25 activity
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Table 1. Genes whose expression is significantly altered by PA25 in W12E cells.

Gene

mRNA (Fold D)

Function/Pathway
Cell Cycle

CDKN1A

2.62

CDK inhibitor 1A (p21)

CDKN1B

22.36

CDK inhibitor 1B (p27, Kip1)

CDKN2A

27.16

CDK inhibitor 2A (p16)

CCNB2

24.38

G2/mitotic-specific cyclin-B2

CCNC

22.87

Cyclin C; regulates RNA polymerase II

CCNE2

22.87

G1/S-specific cyclin-E2

CDK6

23.10

promotes G1/S transition

ANAPC4

23.44

APC subunit 4

RBL1

26.57

retinoblastoma-like 1 (p107)

RB1

23.59

pRb

ATM

23.68

PI-3 kinase; DSB repair; HR

CHK2

22.62

DDR ATM checkpoint effector

CHK1

24.17

DDR ATR checkpoint effector

MRE11A

24.47

MRN complex involved in DSB repair; HR

NBS1

235.70

MRN complex involved in DSB repair; HR

CtIP (RBBP8)

221.01

endonuclease; cooperates with MRN complex; HR

RAD1

267.65

9-1-1 complex member; exonuclease; BER

XRCC4

22.19

dsDNA break repair; NHEJ

FANCB

211.55

Fanconi anemia pathway

FANCC

24.32

Fanconi anemia pathway

FANCL

22.72

Fanconi anemia pathway

CUL2

22.49

E3 ubiquitin-conjugating complex member

CUL3

25.88

E3 ubiquitin-conjugating complex member

UBE2N

22.30

E2 ubiquitin-conjugating enzyme E2N

DNA
Damage
Repair

SKP2

225.93

SCF member; E3 ligase; p27, E7 and E6 degradation

POLM

2.70

gap-filling polymerase; NHEJ

POLQ

22.63

DNA pol theta; interstrand crosslink repair; Alt-NHEJ

TREX1

2.41

3’ repair exonuclease 1

DCLRE1A

23.77

DNA cross-link repair 1A

DCLRE1B

22.39

protection of telomeres against NHEJ

RECQL

23.57

DNA helicase

WRN

22.89

DNA helicase, RecQ-like type 3

RDM1

25.37

RAD52 motif-containing protein 1

MLH3

22.47

mutL homolog, MMR

LIG3

22.31

DNA ligase; BER

RPA4

22.44

rep. protein A4; DSB repair

DSB: double-strand break; BER: base excision repair; MMR: mismatch repair; HR: homologous recombination; TLS: translesion repair; MMR: mismatch repair; NHEJ:
non-homologous end-joining.
doi:10.1371/journal.pone.0075406.t001

slowed over time, and a band that co-migrated with the 8 kB
linearized episome appeared at 5 hours. These results suggested
that PA25 caused alterations in HPV superhelicity, and that a
DSB might be generated by PA25 within a subset of viral episomes
(Figure 9A). Treating with 10 mM PA25 caused a clear retardation
of the HPV episome supercoiled form over time resulting in a
striking, step-like pattern of topoisomers (Figure 9B).
Rad9 and Mre11 were selected as representatives of the PA25
enhancers and repressors for further study since multiple members
of their respective complexes (9-1-1 and MRN) were implicated in
the gene expression and siRNA screens. Rad9 is a member of the

(Figure 8, Table 3), while 4 genes were named PA25 enhancers
since they were required for full PA25 activity.
These results suggested that PA25 might act to alter or damage
episomes resulting in a DDR that either protected the viral DNA
(repressors) or promoted HPV DNA loss from cells (enhancers).
This hypothesis implied that prior to episome loss following PA25
treatment alterations in HPV episome structure might be detected.
The earliest times following PA25 treatment were therefore
examined by Southern blotting. Treatment with 1 mM PA25 for
5 hours revealed compound-dependent effects on episomal DNA
(Figure 9A). The migration of the viral supercoiled form was
PLOS ONE | www.plosone.org
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9-1-1 complex, which acts as a sensor of DNA damage. It was
hypothesized that Rad9 might be phosphorylated in W12E cells in
response to PA25 treatment. Western blotting with a phosphospecific Rad9 (S277) antibody of a 1 uM PA25 treatment time
course demonstrated a sharp increase in Rad9 phosphorylation at
4 h followed by a gradual decline of signal (Figure 10). On the
other hand, no such response to PA25 treatment was elicited in
C33A cells, an HPV-negative cervical carcinoma cell line (Figure
10), again demonstrating the specificity of PA25 for HPV episomal
DNA.
Mre11 stood out as an intriguing PA25 repressor because its
role in DNA repair makes it a plausible candidate to oppose the
action of an agent that acts to cause DSBs. It was hypothesized
that Mre11 inhibition would act to potentiate the action of PA25.
Cells were treated with 100 mM Mirin or vehicle for 24 hours, and
then treated with 1 mM PA25 (Figure 11A) for an additional 24h.
Mirin treatment alone had no effect on HPV episome levels, and
PA25 alone elicited a 90% episome decrease in cells, as expected
(Figure 11A). Strikingly, Mirin dramatically facilitated PA25dependent HPV episome elimination (Figure 11A) suggesting that
Mre11 acts to oppose PA25 antiviral activity. A comparison of
PA25 dose response curves in the presence or absence of Mirin
was then conducted. Mre11 inhibition significantly sensitized HPV
episomes to PA25 resulting in a leftward shift of the IC50 curve
and a significant decrease in the PA25 IC50 from 72 nM to
18 nM (Figure 11B).
The ability of PA25 to directly cause single- or double-strand
breaks in HPV episomal DNA was then directly tested in pull
down experiments by ELCQ (Figure 11C). These experiments
showed that Mirin alone resulted in approximately a 5-fold
increase in HPV DNA end labeling compared with DMSO
controls. On the other hand, PA25 alone resulted in a ,170-fold
increase in HPV DNA pulled down compared to vehicle-treated
controls indicating that PA25 treatment causes significant DNA
strand breakage within viral genomes (Figure 11C). PA25
treatment of Mirin pretreated W12E cells resulted in a ,5-fold
greater amount of end-labeled HPV DNA consistent with Mre11
inhibition sensitizing HPV genomes to PA25-dependent damage
(Figure 11C).

Figure 3. Effects of PA11 and PA25 on expression of cell cycle,
apoptosis, and DDR genes in W12E cells. A. PA11, an inactive
polyamide, does not significantly alter gene expression in W12E cells. B.
PA25 significantly alters the expression of numerous genes in W12E
cells. The expression of most genes is decreased in response to PA25
while 3 are significantly increased.
doi:10.1371/journal.pone.0075406.g003

Figure 4. Experimental design of siRNA screen. A total of 4 experiments were conducted on 4 separate days with cells that were treated with
either vehicle (Set 1) or vehicle plus PA25 (Set 2). Cells maintaining HPV16 (days 123) or HPV31 (day 4) were used in these experiments.
doi:10.1371/journal.pone.0075406.g004
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Figure 5. Hierarchical clustering of all data points (DCt) from 4 separate siRNA screen experiments outlining effects of 240 siRNA
genes on loss (+DCt, red) or gain (2DCt, blue) of episomes in the absence of PA25. All genes are aligned on the y-axis (left). The columns
represent experiments conducted on days 123 (cells maintaining HPV16) and day 4 (cells maintaining HPV31).
doi:10.1371/journal.pone.0075406.g005

Figure 6. Heat map of matrix examining effects of 22 siRNAs on the expression of the same 22 genes measured by Q-PCR using
gene specific primers. All 22 siRNAs were found to specifically down-regulate the appropriate target gene as seen by the mid-linear diagonal effect
in the heat map.
doi:10.1371/journal.pone.0075406.g006
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Table 2. Genes identified in the siRNA screen that significantly alter episome levels in cells under conditions of normal
maintenance.

Gene

Episomes (Fold D)

Activity

Repair

ATM

23.81

PI-3 Kinase; DSB repair

HR

RTEL1

26.95

ATP-dependent helicase; HR suppressor

HR

RUVBL2

23.37

helicase essential for DSB repair

HR
FA

FANCC

24.13

Fanconi anemia pathway

FANCF

2.66

Fanconi anemia pathway

FA

FAN1 (KIAA1018)

23.62

FANC-associated exonuclease

FA

RAD23A

3.03

ubiquitin chain receptor

NER

LIG4

3.43

DNA ligase; ssDNA break repair

NHEJ

POLM

23.57

gap-filling polymerase

NHEJ

NEIL3

2.96

DNA glycosylase

BER

RAD1

22.81

9-1-1 complex member

BER

TDP1

5.40

Tyrosyl-DNA phosphodiesterase 1

DNA adduct repair

TDP2 (TTRAP)

26.19

Tyrosyl-DNA phosphodiesterase 2

DNA adduct repair

RAD18

23.85

E3 ubiquitin ligase; interacts with Rad6

PRR

UBE2V2

4.15

Lys 63 ubiquitination

error-free DNA syn.

TP53

4.50

tumor suppressor; transcriptional regulator

transcript. reg. of repair

MTOR (FRAP1)

24.06

kinase; central regulator of cell signaling /metabolism

MLH3

27.49

mutL homolog

MMR

DSB: double-strand break; BER: base excision repair; MMR: mismatch repair; HR: homologous recombination; TLS: translesion repair; PRR: post-replication repair;
ICL: interstrand cross-link; NER: nucleotide excision repair.
doi:10.1371/journal.pone.0075406.t002

Table 3. Repressors (Cause Episome Loss with Knockdown) and Enhancers (Cause Episome Gain with Knockdown) of PA25
Activity in W12E cells.

Gene

Episomes (Fold D)

Activity

Repair

MRE11A

23.67

MRN member; Endo-exonuclease

DSB, HR

RUVBL2

23.85

Helicase, acetyltransferase complex member

DSB, HR

RTEL1

23.11

Helicase; resolves DNA 2’ structures

DSB, HR

FAN1

23.07

FANCD2-associated nuclease

HR, ICL

RAD1

22.23

9-1-1 complex; Exonuclease

LP-BER

TP73

23.43

Transcription Factor (p53 family)

Pro-apoptotic

POLI

22.06

DNA Polymerase

TLS

PRMT6

22.30

Methyltransferase

BER

MGMT

24.26

Methyltransferase (alkylating agents)

BER

GIYD1

23.56

Structure-specific endonuclease (alkyl. agents)

Resolves HJs

LIG3

23.14

DNA Ligase (alkylating agents)

BER

RAD23B

22.25

Ubiquitin-mediated proteolytic pathway

NER

RPAIN (MGC4189)

22.17

RPA interacting protein

NER

RNF8

22.16

E3 ubiquitin-protein ligase

DSB

MLH3

22.28

MutL protein homolog

MMR, PRR

TYMS

22.62

Thymidylate synthetase

UBE2N

2.23

E2 ubiquitin-conjugating enzyme

DSB, PRR

SMC3 (CSPG6)

2.85

Maintenance of chromosomes (cohesin complex)

HR

RAD9A

3.03

Exonuclease (9-1-1 complex)

LP-BER

REV1L

2.23

Deoxycytidyl transferase

TLS

Repressors

Enhancers

DSB: double-strand break; LP-BER: long-patch base excision repair; MMR: mismatch repair; HR: homologous recombination; TLS: translesion repair; PRR: postreplication repair; ICL: interstrand cross-link; NER: nucleotide excision repair; HJs: Holliday Junctions.
doi:10.1371/journal.pone.0075406.t003
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Figure 7. Summary scatter plot of the DDCt (y-axis) arrayed from lowest to highest values. The significant genes are indicated by green.
Repressors, those genes that oppose the antiviral activity of PA25, have negative DDCt. Enhancers, those genes that are required for full PA25 activity,
have positive DDCt values.
doi:10.1371/journal.pone.0075406.g007

mediate the antiviral activity of PA25. The MRN and the Rad9Hus1-Rad1 (9-1-1) complexes, in particular, appear to play an
important role in the massive HPV episome loss promoted by
PA25. The expression of Rad1, Mre11 and Nbs1 genes was
altered in response to PA25 treatment. Mre11, Rad1, and Rad9
also emerged in the siRNA screen as highly significant regulators

Discussion
The mechanism by which hairpin N-methylpyrrole-imidazole
polyamides (PAs) act to destabilize and eliminate HPV episomes
from cells was examined. Evidence from PCR arrays, a siRNA
screen, and functional studies suggests that DDR repair pathways

Figure 8. Bar graph of PA25 enhancers and repressors identified in the siRNA screen. The effects of siRNAs targeting the genes on PA25
activity are shown. Knockdown of enhancers, those genes that are required for full PA25 activity, results in a net gain in viral episomes in the presence
of PA25. Knockdown of repressors, those genes that oppose the antiviral activity of PA25, causes an increase in PA25 activity resulting in a greater
loss of HPV episomes.
doi:10.1371/journal.pone.0075406.g008
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Figure 10. Western blot showing effects of 1 mM PA25 over
time on Rad9 phosphorylation in two cervical cell lines, W12E
and C33A. Phosphorylation of Rad9 (S277) peaks in the W12E samples
at 4 h. after which the signal is attenuated over the remaining time
course. A similar phosphorylation event is not noted in the HPVnegative C33A cells. The Rad9 (Pan) Western blots are provided as
loading controls.
doi:10.1371/journal.pone.0075406.g010

feature of its antiviral activity. PAs bind to DNA and cause a
number of biophysical effects such as widening the minor groove,
shrinking the major groove, and stiffening the double helix [29]. In
the context of the HPV open circle or negatively super-coiled
episome, PAs may cause twisting, exposure of ssDNA, or DSBs. In
addition, various DNA repair pathways will recognize the bulky
PAs bound to the minor groove as problematic. A broad DDR is
mounted resulting in the elimination of episomes by a process that
is poorly understood. It is important to note that, unlike the DDR
elicited by damage to cellular genomes, the DDR elicited by PA25
does not result in robust cell cycle arrest or have large effects upon
cell growth or apoptosis. We believe that this difference is
attributable to both the unique niche occupied by HPV genomes
within the nucleus and to the well-known action of the HPV
oncogenes.
The damage to HPV episomes by PA25 is specific according to
the following criteria: 1. Inactive PAs do not trigger a DDR, 2.
PA25 activates a DDR response in HPV episome-bearing W12E
cells that is qualitatively and quantitatively distinct from HPVnegative C33A cells and SiHa cells, which carry integrated copies
of HPV16. These findings indicate that PA25 specifically acts on
HPV in the context of the viral episome, 3. PA25 triggers
phosphorylation of Rad9 in HPV-positive W12E cells but not in
C33A cells, and 4. Pharmacological and siRNA inhibition of
Mre11 potentiates PA25 antiviral activity by sensitizing HPV
genomes. PA25 and other antiviral PAs do not cause measurable
toxicity in HPV episome-bearing cells or HPV-negative cells
indicating that these compounds do not significantly compromise
cell genomes [8,9]. These data are fully consistent with numerous
reports in the literature attesting to the low toxicity of this class of
compound [39,40,41].
It was possible to observe transient alterations in episome
structure attributable to PA25 by focusing on the earliest times of
treatment (Figure 9A and B). A retardation of migration of
supercoiled DNA is noted at the earliest times after treatment.
These changes in electrophoretic migration are attributed to
structural alterations in the supercoiled episome, and not increased
mass due to PA25 binding, since it is highly unlikely that PA25
survives the extensive deprotonation during the DNA isolation
procedure. Also, no such alterations in electrophoretic migration

Figure 9. Southern blots of PA25 treated HPV16 episomes from
W12E cells. A. Southern blot of intact HPV episomes following
treatment over 5 hours with 1 mM PA25. Migration of linearized HPV16
is shown (BamH1). Note retardation of migration of HPV16 Form 1 DNA
(arrow) over time in the presence of PA25, and the appearance of Form
3 viral DNA (linear) at 5 hours of treatment (arrowhead). Open circle
form of HPV is indicated with asterisk. B. Southern blot of episomes
following treatment with 10 mM PA25. Migration of linearized HPV16 is
shown (BamH1). Note the pattern of migration of HPV16 Form 1 DNA
(arrow) over time in presence of PA25 resulting in a step-like
appearance of HPV topoisomers. Open circle form of HPV is indicated
with asterisk.
doi:10.1371/journal.pone.0075406.g009

of episome stability in the presence of PA25. These data, as well as
Southern blots and functional studies, suggest that HPV DNA
episome alteration or damage by PA25 is a key, rate-limiting
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Figure 11. The Mre11 inhibitor Mirin acts as a PA25 sensitizer in W12E cells. A. Mirin has no effect on HPV16 episome levels by itself. PA25
causes ,90% loss of HPV16 episomes in cells pre-treated with vehicle (0.1% DMSO), while showing a ,98% loss of episomes in cells pre-treated with
100 mM Mirin. * p = 0.00001 (two-tailed student’s t-test assuming unequal variance), n = 6, error bars represent standard deviation. B. Mirin (100 mM)
causes a leftward shift in the PA25 dose response curve demonstrating the increased sensitivity of HPV episomes under conditions of Mre11
inhibition. The IC50 in this experiment for PA25 was 72 nM without Mirin (solid boxes), and 18 nM in the presence of Mirin (open diamonds). C. Single
and double strand DNA breaks were detected by ELCQ. PA25 caused an increase in the number of detectable breaks while Mirin significantly
enhanced this effect. The numbers over the bars indicate the fold change in detected HPV DNA from the vehicle (0.1% DMSO) treated control, which
is set at 1.
doi:10.1371/journal.pone.0075406.g011

(PA) sequence. The 6-ring PA bent DNA 5.4u per helical turn
while 8-ring PAs bent DNA 0, 3.0 and 3.7u per turn under
conditions benchmarked by straight DNA and an A5 sequence
bent 18u per turn [42]. The stiffening of entire helical turns of
DNA by PA25 could cause, for example, unequal distribution of
supercoiling in an episome, resulting in unusual topologies or
stretches of ssDNA that are recognized as damaged sites by the
DDR. The work described here clearly shows that PA25 elicits a
robust and complex DDR in cells carrying HPV episomes, but not
in cells that have integrated HPV16 DNA (SiHa) or are HPV
negative (C33A). DNA twisting and breaks may arise because of
stress from PA25 binding within the HPV genome that is
impossible to mitigate by unwinding because of its circular nature.
Mre11 protects the viral genome from PA25 under these
conditions.
The MRN complex is particularly interesting as a PA25
repressor. Both MRE11 and NBS1 genes are down-regulated in

occur in the matched, BamH1-linearized samples, indicating that
an alternative, perhaps relaxed, structure of the HPV supercoil is
responsible. In the presence of 10 mM PA25, the appearance of a
series of HPV topoisomers over time was clearly observed (Figure
9B). We hypothesize that these topoisomers arise by topoisomerase
resolution of PA25-generated stress within HPV supercoiled DNA.
After 5 hours in the presence of 1 mM PA25, a band co-migrating
with the 8 kb linearized HPV standard also appeared suggesting
that dsDNA breaks are occurring within the altered supercoiled
episome (Figure 9A). The data from end labeling of HPV genomes
coupled to Q-PCR (ELCQ; Figure 11C) also demonstrates the
generation of PA25 induced breaks within the viral genomes.
It is important to note that PAs and other minor groove-binding
agents affect DNA structure in a number of quantitative and
qualitative ways [29,30,31,32]. Most recently, 6- and 8-ring
polyamides considerably smaller than PA25 were shown to affect
DNA bending in a manner dependent on DNA and polyamide
PLOS ONE | www.plosone.org

13

October 2013 | Volume 8 | Issue 10 | e75406

DNA Damage Repair Genes and HPV Episome Stability

response to PA25 treatment, as is the MRN structural and
functional partner CtIP (RBBP8), which mediates DSB resection
during repair [27]. MRE11 also emerged as a strong repressor of
PA25 in the siRNA screen, which led us to consider whether
pharmacological inhibition of Mre11 would potentiate PA25
antiviral activity. Since Mre11 is generally regarded as both a
sensor and central mediator of DSB repair [43], our data strongly
argue that PA25 initiates HPV episome elimination by introducing
DSBs within the HPV episome. The altered regulation of
numerous other DSB repair genes by PA25 including ATM,
CHEK2, RAD1, and XRCC4 is fully consistent with this idea
(Table 1).
Drugs that act within DDR pathways to sensitize cells to
radiation or to chemotherapeutic agents have the potential to
enhance and extend cancer therapy by magnifying the toxic effect
within the targeted cells [44]. These approaches work by
preventing repair and allowing the accumulation of extensive
DNA damage that proves toxic to the targeted cells. Mirin is an
inhibitor of Mre11-associated exonuclease activity that was
identified in a forward genetic screen, and subsequently shown
to block the ability of MRN to repair DNA via HR [34]. We show
here that Mirin makes viral episomes more susceptible to PA25 in
a manner that is analogous to radiation and chemotherapeutic
sensitizers. This observation was made after Mre11 emerged from
the siRNA screen as a repressor of PA25 antiviral activity. These
results--that PA25-dependent elimination of episomes is repressed
by Mre11 and sensitized by Mirin--provides a powerful argument
that PA25 acts to damage viral episomes, causing them to be
eliminated from cells. It should be noted that PA25 is not toxic to
cells at concentrations vastly exceeding those used in this study,
and therefore the effect on episomes is a specific DNA damage
event that is primarily manifested by viral DNA elimination rather
than cell death [8,9]. The lack of apoptosis genes affected by PA25
is consistent with this concept (Figure 3, Table 1).
The heterotrimeric Rad9-Hus1-Rad1 (9-1-1) complex is also
found to play a role in PA25-dependent loss of HPV episomes.
The 9-1-1 complex is a processivity clamp related to PCNA that
acts as a scaffold to bring DDR and checkpoint effectors to sites of
DNA damage [45,46]. The 9-1-1 complex has been found to
associate with and stimulate numerous checkpoint and base
excision repair enzymes, and therefore may serve to coordinate
DNA repair and checkpoint control [47,48,49]. RAD1 emerged as
the gene most altered by PA25 in expression studies (Figure 3,
Table 1). Rad1 and Rad9 were also both identified in the siRNA
screen as highly significant, but oppositional, modulators of PA25
activity: Rad1 acts to repress PA25 activity while Rad9 is an
enhancer (Figures 7 and 8, Table 3). The binding of hairpin
polyamides, such as those employed in this study, is known to
expand the minor groove and shrink the major groove of DNA. In
contrast, association of the 9-1-1 complex with DNA has the
opposite effect, resulting in a contraction of the DNA minor
groove and an expansion of the major groove [46]. For these
reasons the 9-1-1 complex is a good candidate sensor and
coordinator of PA25 antiviral activity that may serve to recruit an
enzymatic mechanism to the HPV episome resulting in its ultimate
destruction. At present it is not understood why Rad1 serves as a
PA25 repressor while its 9-1-1 partner Rad9 acts as an enhancer.
This difference may be attributable to alterations in 9-1-1
stoichiometry following siRNA treatment, or to differences in
their reported DNA binding properties [46].
The process of studying the PA25 mechanism of action required
that the effects of 240 DDR siRNAs also be observed on normal
HPV stability in the absence of PA25. HPV16 and HPV31
episome levels fluctuated in cells in response to a panel of DDR
PLOS ONE | www.plosone.org

siRNAs in a similar manner even though the W12E cell line was
derived from a cervical biopsy while the cells maintaining HPV31
were generated in a laboratory from foreskin keratinocytes. The
four experiments used in these studies included three experiments
(days 123) utilizing W12E cells and 1 experiment (day 4) using
keratinocytes maintaining HPV31 episomes. A previous report
indicated that these genotypes use different modes of DNA
replication in cells [50]. Using hierarchical clustering (Figure 5) we
established that the day 4 (HPV31) data falls within the range of
similarity established for days 123 (HPV16). Using this approach,
multiple HR and FA pathway siRNAs were identified as
significant modifiers of normal HPV episome levels (Table 2).
FANCC and FANCF were found to contribute to HPV episomal
stability (Table 2). Since the FA and HR pathways were previously
implicated in HPV persistence and the viral life cycle
[9,16,22,24,28], these correlations serve as further support for
the validity of our studies, and further implicate these pathways as
central to the survival and persistence of HPV episomes in cells.
Likewise siRNAs for TP53 and MTOR significantly affect HPV
episome levels--siRNA to TP53 resulted in an increase in episomes
while MTOR knockdown decreased episome levels. Both of these
proteins are known targets of HPV E6, which is required for
episome maintenance in cells [51,52,53].
A number of novel genes are also identified as highly significant
in normal HPV episome maintenance by our siRNA study (Table
2). Members of excision repair, mismatch repair, and other DDR
pathways are highly significant in the siRNA screen and therefore
excellent candidate modifiers of episome stability (Table 2).
Notably, both TDP1 and TDP2, the only known human genes
whose activities are required for removing trapped DNA cleavage
complexes of topoisomerase I (TDP1) and topoisomerase II
(TDP2) [54,55], were both identified as regulators of HPV
episome stability. TDP1 knockdown causes a net gain of episomes
while TDP2 knockdown results in a net loss (Table 2). These genes
were originally identified by their ability to remove topoisomerase
cleavage complexes created in the presence of topoisomerase
poisons. However, there is a growing appreciation that DNA
metabolic events including DNA damage, ssDNA breaks, and
misinsertion of ribonucleotides can trap topoisomerase I, while
transcription-related events and abasic sites may cause trapping of
topoisomerase II [56]. We therefore hypothesize that the trapping
of both topoisomerase I and II on HPV episomes are events that
must be overcome for successful HPV episome maintenance.
Together, these observations from the siRNA screen make a
significant contribution to an expanding knowledge base that seeks
to understand the role of DDR pathways in normal HPV episome
maintenance.
It is apparent that HPV episome stability can be greatly
diminished under certain conditions. Here we show a role for
multiple DDR genes in mediating the loss of HPV DNA in
response to PA25. It was previously shown that the ATR/Chk1
pathway does not play a role in PA25-mediated episome loss, yet
does have its own role in controlling viral DNA stability [9].
However, it should be noted that it remains to be determined in
both cases how viral DNA destruction is executed by the cell. We
have shown here that the 9-1-1 complex is a candidate sensor that
may play a role in calling for HPV episome removal, but the
elements that mediate viral DNA destruction remain unknown.
Likewise, Mre11 and MRN appear to play a role in stabilizing
episomes against PA25-dependant damage, but the mediators of
viral DNA destruction downstream of Mre11 remain to be
determined. We believe that understanding the genes and
processes that mediate HPV DNA instability and destruction has
the potential to inform us about such diverse topics as viral
14
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persistence, interferon-mediated viral DNA loss, and antiviral
therapy. Finally, it is interesting to consider the application of
similar strategies to other DNA viruses that maintain their
genomes as extrachromosomal plasmids.

below 5%, and fairly consistent across all experimental days. Table
S1, Summary of gene expression changes in HPV-negative (C33A)
and HPV-positive (SiHa) cells following treatment with 10 mM
PA25. Table S2, CVs for Each Experimental Day. Table S3, All
240 Genes in Dharmacon DDR siRNA Library. Table S4, PCR
primer sequences for 22 DDR genes employed in matrix for
verification of siRNA specificity. Statistical Methods S1, Control
Ct values (Step 1) and Experimental Ct values (Step 2).
(DOCX)

Supporting Information
File S1 This file contains Figure S1-Figure S4, Table S1-Table
S4, and Statistical Methods S1. Figure S1, Scatter plot showing
effects of PA25 on gene expression of cell cycle and DDR genes in
the HPV-negative C33A cervical cancer cell line and in the
HPV16 positive SiHa cervical cancer cell line. A total of 7 genes
were found to have altered expression in both cell types with only a
single gene difference between both. Also see Table S1 in File S1.
Note similarity between the two graphs for comparison to Fig. 3B
and Table 1. Figure S2, FACS analysis was conducted on cells
treated with vehicle (control) or with 10 mM PA25 for 48 h. Values
indicated are the % Total cells within the relevant cell cycle
period. Figure S3, Control data showing the resulting control
mean and SD’s from each of the experimental days from siRNA
screen. Figure S4, The coefficient of variation values are well
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